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Background: The Bergen 4-day treatment (B4DT) is a concentrated exposure-based
treatment for patients with Obsessive-Compulsive Disorder (OCD) delivered during four
consecutive days. The B4DT has in a number of effectiveness studies demonstrated
promising results as approximately 90% of patients gain reliable clinical change
post-treatment and nearly 70% are recovered on a long-term basis.
Methods: The current study is the first randomized controlled trial evaluating the effects
of the B4DT. Forty-eight patients diagnosed with OCD were randomized to B4DT,
self-help (SH), or waiting list (WL) with 16 patients in each condition. All participants
randomized to the B4DT underwent the treatment without any attrition.
Results: The B4DT yielded significantly better effects than control conditions on
measures of OCD, depression, and generalized anxiety. The response rate (≥35%
reduction of the individual patient’s pre-treatment Y-BOCS score) was 93.8% in B4DT,
12.5% in SH and 0% in WL, while remission rate (response criterion is fulfilled and the
post-treatment Y-BOCS score is ≤12 points) was 62.5%, 6.3%, and 0%, respectively.
Furthermore, patients who had received the B4DT, showed improved work- and social
functioning. None of the patients treated with B4DT showed signs of deterioration.
In comparison, one patient in the SH condition was in remission, and one showed
significant clinical improvement, whereas the remaining showed no change.
Conclusion: The results indicate that the B4DT is an effective treatment for patients
suffering from OCD.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT02886780.
Keywords: obsessive-compulsive disorder, OCD, ERP, RCT, B4DT, group therapy
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INTRODUCTION
Cognitive behavior therapy (CBT) including exposure and
response prevention (ERP) is widely recognized as the treatment
of choice for patients suffering from obsessive-compulsive
disorder (OCD; Öst et al., 2015). A number of meta-analyses have
shown that this treatment approach can be delivered successfully
in a number of different formats including individual or group, in
a concentrated form or weekly over several months (Abramowitz,
1998; Rosa-Alcázar et al., 2008; Öst et al., 2015).
However, patients with anxiety disorders rarely receive
evidence based treatment (Shafran et al., 2009). Thus, self-help
(SH) may be the only realistic treatment alternative for a
substantial number of patients. In areas with low prevalence of
competent therapists, the realistic alternative for many patients is
the use of various SH manuals. Patients treated with SH can learn
(e.g., from a workbook) about their disorder and how to apply
treatment techniques to their own problems. SH can be delivered
unassisted (pure SH) or guided (assisted by a clinician). Pearcy
et al. (2016) published a meta-analysis of 18 studies (N = 1570)
summarizing available RCT’s on SH for OCD, showing an average
effect size of 0.51. Effect size for self-administered SH was
smaller (g = 0.33) than for therapist-assisted SH (g = 0.91).
Pearcy et al. (2016) concluded that there is a growing body of
literature supporting the use of SH for OCD, but the authors also
underlined the need for further studies in this area.
Even though group treatment approaches are effective, they
tend to be associated with lower effect sizes as compared to
individual treatments (Öst et al., 2015), which is in line with our
clinic’s previous research, which indicates that more than 50% of
the patients remained unchanged after a 12-session CBT group
(Håland et al., 2010). Five to eleven years later, 62% of the patients
were available for long-term follow-up interviews, and among
these 40% were recovered and another 10% were improved, while
50% were unchanged (Sunde et al., 2017).
Recently, a highly concentrated CBT format including ERP,
the Bergen 4-day treatment (B4DT), has shown promising results
in a number of effectiveness studies (Havnen et al., 2014, 2017;
Hansen et al., 2018, 2019). The B4DT can best be described
as “individual treatment delivered in a group setting” because
it is delivered to a group of 3–6 patients by the same number
of therapists. The 1:1 ratio between patients and therapists
ensures individually tailored exposure treatment, and the group
setting provides the benefit of observing and working together
with other patients.
More than 90% of the patients can expect relevant clinical
change post-treatment, and nearly 70% are recovered on a
long-term basis (Hansen et al., 2018, 2019). The approach is
highly accepted by the patients, and there are essentially no
dropouts. One of the strengths of the B4DT is that it was
developed within an ordinary clinical setting, with low selection
of patients, thus achieving high ecological relevance. Also, results
of the B4DT has been replicated with new samples and new
therapists (Havnen et al., 2017; Hansen et al., 2018), at new
sites (Kvale et al., 2018; Launes et al., 2019) and in a different
country (Davíðsdóttir et al., 2019). The B4DT has also been
shown to significantly improve depressive symptoms as well as
symptoms of generalized anxiety (Havnen et al., 2014; Hansen
et al., 2018; Launes et al., 2019). However, the B4DT has not yet
been evaluated in a randomized controlled trial (RCT).
The aim of the current study is to compare two
exposure-based interventions for obsessive compulsive disorder,
namely the B4DT and a SH ERP intervention based on Foa and
Kozak’s (1997) approach in an RCT with waiting list (WL) as a
control condition.
Based on the B4DT effectiveness studies, we expected the
B4DT to be highly accepted by the patients. Also, we expected
the B4DT to be superior to SH and to the WL condition
on primary as well as secondary treatment outcome measures.
Due to the inconclusive findings in the literature regarding
self-administered SH, a clear hypothesis regarding the effect of
this intervention seems premature. We also expected that the
effects gained from the B4DT would be maintained at 6-month
follow-up as seen in the previous effectiveness studies. Based on
previous findings, we also expected significantly larger reduction
in secondary outcome measures of depression, anxiety, work and
social adjustment in the patients receiving B4DT, as compared to
the other two conditions.
METHOD
Design and Randomization
The present trial is a randomized study where eligible OCD
patients were randomized to one of three conditions, namely the
B4DT, a 3-month SH intervention, or a 3-month WL. Based on
ethical considerations, patients in the SH or in the WL condition
were offered the B4DT after post-assessment if they still wanted
treatment. Thus, there are no 6-month follow-up data on the
patients in the SH- and WL condition.
Patient inclusion numbers were randomized (in blocks of
six) using the online program Research Randomizer1 by an
independent researcher at Karolinska Institutet, Stockholm,
Sweden, to B4DT, SH or WL prior to study start. Directly
after being included and receiving a study number, the patients
were informed about their assignment. The enrollment was
consecutive, so all patients referred to the clinic between August
2016 and September 2017, fulfilling the inclusion criteria and
none of the exclusion criteria, were invited to participate in
the study. If the patient agreed to participate, an informed
consent was signed.
Inclusion and Exclusion Criteria
Patients 18 years or older were eligible for inclusion in the
study if they fulfilled the criteria of an OCD-diagnosis and
had a Y-BOCS score of 16 or more; were fluent in Norwegian,
and willing to sign the informed consent form. Exclusion
criteria were: bipolar disorder, psychosis, ongoing substance
abuse/dependence, hoarding behavior, intellectual disability
based on previous medical history, eating disorder in need of
medical attention, unwilling to refrain from anxiolytic drugs
during the 4 days of treatment, ongoing suicidal ideation,
1https://www.randomizer.org
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unstable dose of antidepressant with recent dose-change within
the last 4 weeks, and living more than 1.5 h drive by car/train
form the treatment location. Also, patients who had undergone
a previous full course of CBT treatment for OCD were excluded,
due to an ongoing national trial targeting this group.
Participants
The trial was conducted at an outpatient clinic in Kristiansand,
part of the specialist health care in Southern Norway. Patients
were referred from their general practitioner to a local outpatient
clinic, and if their disorder was considered severe enough
(Y-BOCS ≥ 16) to grant them treatment in the specialist
health care, patients with OCD or suspected OCD, were
referred to the specialized outpatient OCD-team at Solvang,
Sørlandet Hospital. Eligible patients were informed orally and
in writing about the study and the randomization procedure.
The patients who declined participation were offered individual
exposure-based CBT.
As part of standard care, potential participants were assessed
using a standardized anamnestic interview which included
the Mini-International Neuropsychiatric Interview (M.I.N.I.;
Sheehan et al., 1998) and the Yale-Brown Obsessive Compulsive
Scale (Y-BOCS; Goodman et al., 1989).
During the inclusion period, 66 patients were considered
for participation. 14 participants were excluded as they did not
fulfill the inclusion criteria, or they fulfilled exclusion criteria
for the study. One patient declined to participate in the study
before signing the informed consent. One patient withdrew her
consent within days after inclusion, as she was ambivalent about
the concentrated group format. The other 50 proceeded to the
diagnostic interview (see below). After this interview, one patient
was excluded due to subclinical OCD and one because the
SCID-interview revealed psychotic symptoms. See Figure 1 for
flow chart describing patient flow throughout the study.
Background Data
Thirty-eight (79%) of the participants were female, and the
mean age of the participants was 30 years, 31 (64%) were
single. With respect to work status; 17 (35%) were working, 9
(19%) were students and 22 (46%) were on welfare benefits.
Self-reported age of OCD onset was 15.52 (SD = 10.61) and the
mean duration of OCD was 14.48 (SD = 10.15) years. There
were no significant differences between the patients randomized
to the three conditions regarding these variables. A summary
of the participant’s background and diagnostic information is
presented in Table 1. The sample had a wide range of OCD
symptoms as indicated by scores on the DOCS-SF: 24 had
obsessions related to contamination, 32 to being responsible
for accidents, 19 to sexual, religious violence, or taboo related
themes, 18 to symmetry/ordering, and 21 reported other contents
of the obsessions. There were only 13 patients reporting just
one type of OCD.
Pre-treatment OCD Severity
Forty-one (85%) patients had a severe OCD (Y-BOCS
of 24–38), whereas seven (15%) had a moderate OCD
(Y-BOCS of 18–23). Mean Y-BOCS scores pre-treatment
were 27.17 (SD = 4.08). There were no significant
differences in pre-treatment OCD-severity between the
conditions (p = 0.702). Twenty-one patients (44%) were
rated as having excellent insight, sixteen had good insight
(33%), eight (17%) had fair insight, and three (6%) had
poor insight, as measured by Y-BOCS item 11. There
were no significant differences in insight between the
conditions (p = 0.514).
Comorbidity
Forty-two (87%) of the patients had comorbid disorders (number
of comorbid disorders ranged from one to six with a mean of 2.1,
SD = 2.0). Fourteen patients (29%) had one comorbid disorder,
11 (23%) had two, six (12.5%) had three, seven (14.5%) had
four, three (6%) had five, and one (2%) person had six comorbid
disorders (for details see Table 1). There were no significant
differences between the three conditions in total number of
comorbid disorders, but there were significantly more patients
with a comorbid depressive disorder in the SH- and waiting-list
condition, compared to the B4DT-condition.
Pharmacological Treatment
Use of medication was registered at the initial interview. In
the total sample, 12 (25%) used SRI/SSRI/SNRI, three (6%)
used anti-psychotic medication, five (10%) had sleep medication
prescribed for use when needed, and for three of the patients
the sleep-medication was benzodiazepines; two used Ritalin (4%),
and three (6%) used antiepileptic medication. There were no
significant differences in the three conditions with regard to
the use of psychotropic medication (see Table 1). Patients with
and without psychotropic medication did not differ on Y-BOCS
scores, t(46) = 0.035, p = 0.972, PHQ-9 scores, t(46) = 0.332
p = 0.332, or GAD-7 scores, t(45) = −0.239, p = 0.812,
at pre-treatment. Patients on SSRI were encouraged to keep
medication doses unchanged prior to and during the 4-day
treatment period, and no changes in SSRI medication were
reported at the post-treatment assessment. Patients were asked
not to use any anxiolytics during the 4 days of treatment or
to seek concurrent treatment for their psychological problems
during the 4-day period. All patients reported that they adhered
to this request.
Assessment
The patients were asked to answer (online) a number of disorder-
relevant questionnaires prior to randomization, and at post-
treatment (except for WSAS which was administered only at pre-
treatment and follow up for the B4DT group). For the patients
who were randomized to the B4DT, these questionnaires were
also administered at 3- and 6-month follow-up.
Diagnostic Interviews
After the patients were informed about the result of the
randomization, they underwent a SCID-I interview (First et al.,
2015) and a Y-BOCS interview conducted by an independent
assessor by phone. Reliability and validity of conducting Y-BOCS
interview by phone is supported by previous research (Baer et al.,
1993). All participants were interviewed within a week prior to
the intervention started. Post-treatment/waitlist assessment was
done within 1 week after the condition ended. The OCD-module
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FIGURE 1 | CONSORT flow chart. Reasons for exclusion were: other primary diagnosis (n = 3), sub-clinical OCD (n = 7), drug abuse (n = 2), inpatient (n = 1), and
unstable medication (n = 3), declined to participate (n = 2).
of the SCID and the Y-BOCS-interview were repeated at 3- and
6-month follow-up.
All Y-BOCS and SCID-I interviews for DSM-5 were
conducted by specially trained and independent assessors. All
the assessors were clinical psychologists, and had first received
theoretical lessons in how to use the scales as well as practical
instructions and video demonstrations which illustrated different
scores on the items of the scales. To be qualified for the study, the
assessors had received three videotaped full SCID-I interviews,
and Y-BOCS interviews which they rated, and in order to
proceed, the candidate had to demonstrate a minimum of 80%
accuracy compared to an expert on 2/3 of the interviews. On
Y-BOCS a maximum difference of ±2 points was employed.
The assessor then had to perform three SCID-I interviews and
Y-BOCS interviews with referred OCD-patients, which were
videotaped and rated by a blinded expert (same requirements as
above). All the phone interviews were taped. Adherence checks
were performed on a random selection of 20% of the taped
interviews. The checks were conducted monthly and feedback
was given to the assessors. Inter-rater reliability both for OCD
diagnosis before treatment (κ = 1.00) and Y-BOCS were excellent
(intraclass correlation = 0.97).
Therapists
In each treatment group, the patient to therapist ratio was 1:1.
The groups were led by an expert on the 4-day format. All
therapists had taken part in the national OCD-training program
(Kvale and Hansen, 2014), or had documented equivalent
training. Prior to participation, all therapists had participated in
a minimum of two B4DT groups where they were independently
rated as competent by two B4DT experts by using items of the
OCD CORE competencies instrument (Steketee, 1993) relevant
for the 4-day format. In order to become a leader of a B4DT
group, it was required to have participated in a minimum of
six B4DT groups and rated as competent by two independent
assessors. Then these therapists functioned as leaders of a
minimum of two B4DT group prior to the trial, and were rated
as competent by two B4DT experts. Therapists included two
psychiatrists, four psychologists and one psychiatric nurse, all
with extensive experience as B4DT OCD-therapists.
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TABLE 1 | Demographic and diagnostic characteristics.
Total B4DT SH WL χ2/F p
Demographics
Age 30.35 (11.08) 33.35 (14.93) 27.75 (7.09) 30.06 (9.75) 0.99 0.38
Age at OCD onset 15.52 (10.61) 19.13 (14.25) 14.38 (8.72) 13.06 (7.20) 1.48 0.24
OCD duration 14.48 (10.15) 13.63 (8.62) 12.88 (10.15) 16.94 (11.64) 0.72 0.49
n (%)
Female gender 38 (79) 14 (88) 13 (81) 11 (69) 1.77 0.41
Single 21 (44) 5 (38) 10 (63) 6 (31) 3.56 0.17
Work status 0.88 0.93
Student 9 (19) 4 (25) 3 (19) 2 (13)
Employed 17 (35) 5 (31) 6 (38) 6 (38)
Welfare benefits 22 (46) 7 (44) 7 (44) 8 (50)
Psychotropics 21 (44) 5 (31) 8 (50) 8 (50) 1.52 0.47
Comorbidity
# of disorders 2.15 (1.56) 1.50 (1.10) 2.56 (1.55) 2.38 (1.82) 2.23 0.12
No comorbidity 6 2 1 3
GAD 15 5 5 5
Major depression 17 1 9 7
Dysthymia 9 0 6 3
Panic/agoraphobia 15 2 7 6
Social anxiety 9 3 4 2
Specific phobia 5 4 1 0
Insomnia 9 3 3 3
PTSD 4 1 2 1
ADHD 4 1 0 3
Skin picking 4 0 2 2
Other 9 3 2 4
Therapist Meetings Throughout the 4-Day Treatment
The patients were informed that the therapists worked as a team,
and that the group leader would decide throughout the treatment
which therapist would work with which patient during the next
session. If considered feasible, each patient would work with
more than one therapist in order to increase generalizability. Each
day there were pre-scheduled brief therapist meetings throughout
the day in order to ensure that the group leader and each therapist
were informed about the progress and challenges for each patient.
As a rule of thumb, the most experienced therapist worked with
the most challenging patient, and also assisted and supervised in
other exposure treatments when needed.
Treatment
For a more comprehensive description of the treatment,
see Launes et al. (2019).
The B4DT
Treatment preparation
The content and format of the B4DT was thoroughly described
to eligible patients prior to inclusion. All were informed that
the treatment needed to have their full attention, which meant
that they could have no other appointments during the 4 days,
and no appointments during the evenings of Day 2 and 3. If
working, they were asked to take sick leave from work during
the treatment. It was explained that it was essential to actively
approach situations that triggered the OCD, and to learn new
ways to deal with the anxiety and discomfort. It was underscored
that the patients prior to the 4 days needed to prepare suitable
exposure tasks, and were told that “the tasks that the OCD dislikes
the most,” often were the ones that would create the largest
change. Consequently, hierarchies where the exposure tasks are
rank ordered based on the anxiety they are assumed to elicit,
were not employed. After the patients were informed about the
treatment, a modified version of the Borkovec and Nau (1972)
“Treatment expectancy Scale” was applied. This contained four
questions, namely (1) How logical does this treatment approach
seem to you? (2) Would you recommend it to a friend? (3)
What is the likelihood that you will fully dedicate the 4 days to
the treatment and follow the treatment recommendations? (4)
What do you think the likelihood is that you will benefit from
the treatment? All questions were rated on a scale from 0 to
100. A rating below 70 was taken as an opportunity to explore
and clarify misunderstandings. The week prior to the treatment,
the leader called each patient in order to welcome them to the
B4DT and to ensure that they were ready and had prepared
relevant exposure tasks. The four questions addressing treatment
expectancy were repeated. The call was scheduled to 15 min.
Day 1 psycho-education and exposure preparation (3–4 h)
The psychoeducation focused on the rationale behind ERP in
the B4DT treatment, as well as important principles for change.
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Throughout the presentation, the OCD was externalized and
described as a disorder that prevents them from living the life
they want. It was underscored that the regulation of anxiety
and discomfort through obvious or subtle avoidance and rituals
maintain the symptoms, which means that in order to get
rid of the OCD it is necessary to actively approach situations
and stimuli that elicit OCD relevant anxiety and discomfort
in order to learn to master it differently. In line with this
anxiety was labeled “the raw material for change.” In addition,
it was underscored that OCD typically demands a 100% certainty
in situations when this is not an option, and that one goal was to
learn to deal with a certain amount of uncertainty in the relevant
situations. As a consequence, behavior experiments aimed at
disconfirmation of catastrophic believes were not employed.
Relevant exposure tasks were decided upon based on suggestions
from the patients.
The LET intervention
One of the main features of the B4DT is to teach the patients
to approach whatever elicits OCD-related anxiety or discomfort,
and to help them systematically learn how to “LEan into
The anxiety” (LET-technique) instead of employing obvious or
subtle avoidance. During the exposures, their task is to clearly
demonstrate that they are doing something that is incompatible
with practicing OCD-behaviors. It is underscored that if they
are doing exposures and simultaneously try to neutralize their
anxiety by following the demands of their OCD (keep their
“OCD-project”), this will basically lead to discomfort without
change. The patients are told that the OCD-project is often so
integrated in their behaviors that they are typically not aware of
the subtle avoidances and ritualizing, and that one of the main
tasks for the therapist is to help the patient to be aware of these.
If, for example, the task is to touch something that might trigger
anxiety and discomfort due to potential risk of contamination,
then hesitation, partially touching, and preventing spreading of
the germs are seen as part of an OCD-project aimed at reducing
anxiety and discomfort, which is to be replaced by an intention to
“let go” of the control. Loop tapes can be used in these situations
to maximize uncertainty, e.g., using repeated statements such
as “I cannot be certain whether or not I got contaminated
by touching all these objects.” Throughout the treatment it is
systematically underscored that it is essential to first learn to do
exposures with the correct technique (without subtle avoidance
or rituals), and then to apply this approach to the tasks that
“the OCD dislikes the most.” Whenever the patient starts any
exposure exercise without clearly demonstrating that they are
applying the LET-technique, the therapist will always suggest that
the patient repeats an exposure that is done in accordance with
the LET-technique. During the 2 days of exposure, therapists
assisted each patient in practicing the LET-technique consistently
whenever anxiety or discomfort is elicited, and the patient was
encouraged to approach as many anxiety- or discomfort eliciting
situations, contexts, and thoughts as possible.
Day 2 and 3
Day 2 started with summarizing the principles for the B4DT
followed by an invitation to revise the individual exposure tasks
in order to ensure that each patient had included all relevant
tasks. The LET-intervention was then demonstrated. Throughout
Day 2 and 3 (8 h each day), patients were engaged in individually
tailored and therapist-assisted ERP in as many OCD-relevant
settings as possible (including their home and sometimes their
work) with continued self-administered practice in the evening,
using the LET-intervention. The group met as a minimum in
the morning, at lunch and in the afternoon where each patient
shared their progress with the group and therapists. Specifically,
they were asked to rate their own exposure performance on a
scale from 1 to 6, where 6 indicated that they were “leaning
fully into” the exposures. If they rated themselves less than 6,
they were asked in which situations they were holding back, and
what the “holding back” consisted of (e.g., hesitant exposures
instead of starting right off), and they were encouraged to correct
this during the next exposure. If considered useful, the patient
reported progress to the therapist throughout the afternoon by
brief text messages (e.g., “6” indicating that they were doing
exposures in accordance with the LET-technique). In some cases,
the therapist assisted the patient also in the evening in form of
brief phone consultations. As a minimum, all patients reported
back to the therapists once in the evening, typically at 9 pm with a
text message stating their performance on the LET-intervention.
If regarded as necessary, the therapist called the patients in order
to troubleshoot exercises and to motivate patients to keep up
with their LET exercises. Relatives and friends were invited to a
psycho-educative meeting in the afternoon of day 3 (1.5 h).
Day 4: summarizing and relapse prevention
The last day was allocated to summarizing (“lessons learnt”)
and planning self-exposures for the next 3 weeks. Focus was
on teaching the patients how to be “their own therapists.”
The patients were provided with written information covering
procedures and times for upcoming assessments. At the end, the
patients gave a structured feedback/evaluation of the treatment in
the group setting.
Homework assignments during the first 3 weeks
post-treatment
Participants logged their compliance (online) to the homework
for 3 weeks after the 4-day group treatment. During this period,
they did not have any contact with the clinic.
Follow-up visit at the clinic
Each patient had an individual follow-up meeting at the clinic
about 12 weeks after the 4-day treatment was completed. The
purpose of this appointment was to help the patient summarize
their experiences following the B4DT, and if necessary, to refresh
the principles of how to fight the OCD. No exposure therapy was
done during this follow-up session.
The Self-Help Condition
The patients in the S-H condition received a SH book 1 week after
the initial screening interview. The book is written by Foa and
Kozak (1997), and covers both psychoeducation regarding OCD
and “how-to-do” principles for ERP. Our recent meta-analysis
(Öst et al., 2015) indicated that the range for SH interventions
was 6–24 weeks, with a median of 12, and with 25% of the
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interventions lasting 9 weeks or less. The SH condition in the
current study was 12 weeks from pre- to post-assessment, and
there was no contact between patients and therapists during
this period. Thus, this condition was a pure SH intervention
(self-administered bibliotherapy).
Adherence and Competency
Because the B4DT is delivered in a group setting with 3–6
therapists, it enables direct observation of therapists and
group leader. There is also appointed a designated “second-in
command,” who is responsible for ensuring that the protocol is
followed, and that any deviances reported to the group leader
are dealt with immediately. If the group leader did not comply
with the protocol, the second in command was required to
first notify the group leader and also inform the PI. No such
reports were received.
The LET-intervention was demonstrated for the whole group
of patients and therapists in the morning of Day 2, which enabled
direct observation of adherence to the protocol. Deviances from
the protocol were dealt with directly in the therapist meetings.
In addition to the psychoeducation which is presented Day
1; Day 2, 3 and also 4 start with a joint meeting for all.
Also, everyone met for lunch and for a second meeting at
approximately 3 pm Day 2 and 3. In the afternoon Day 3, there is
a meeting for family and relatives. Deviations from the protocol
are dealt with directly in the therapist meetings.
Directly after the treatment is completed, each therapist
answers a brief questionnaire concerning whether the group
was led in accordance with the protocol and with adequate
competence, and whether each patient had been treated in
accordance with the plan. Each question was rated “red”
meaning not adequate/deviant; “yellow” meaning with some
adjustments/deviations and “green” meaning adequate/in
accordance with protocol. There were reported two “yellow”
deviances. One addressing that a therapist had become ill
the afternoon of Day 3 but the patient was adequately taken
care of by another therapist. The other was addressing that
the video camera did not work properly during all parts of
the psychoeducation.
To enable external experts to assess if the protocol was
followed, the psychoeducation, demonstration of the LET-
intervention, all joint meetings between patients and therapists,
all therapist meetings as well as the psychoeducation for the
family/relatives were videotaped. Two independent assessors
scored all parts of the three first groups and a 50% random
selection of the rest. The assessment was done on a three-point
scale: “red” = not in accordance with protocol, “yellow” = partly
deviant and “green” = in accordance with protocol. All video
recordings were scored “green” by both independent assessors.
Measures
Yale-Brown Obsessive-Compulsive Scale (Y-BOCS;
Goodman et al., 1989)
The Y-BOCS is regarded as the gold standard for assessing
the severity of OCD symptoms. It consists of a symptom
checklist covering obsessions and compulsions and a severity
scale (Goodman et al., 1989). The severity scale comprises 10
items, rated on a 5-point Likert scale ranging from 0 (no
symptoms) to 4 (severe symptoms). The total score ranges
from 0 to 40. Y-BOCS has excellent inter-rater reliability and
moderate to good internal consistency. Insight was measured by
Y-BOCS item 11.
Structured Clinical Interview for DSM Disorders
(SCID-I; First et al., 2015)
The SCID-I covers Axis I psychiatric disorders according
to DSM-5.
The Patient Health Questionnaire 9-Item (PHQ-9;
Kroenke et al., 2001)
The PHQ-9 is based on nine criteria for diagnosing depression
in DSM-IV. Each item is reported on a four-point Likert scale
(0, not at all; 3, almost every day), and the answers refer to
the past 2 weeks. PHQ-9 has good psychometric properties and
suggested cut-off scores for detecting major depressive disorder
range between 8 and 11 (Titov et al., 2011; Manea et al., 2012).
The Generalized Anxiety Disorder 7-Item (GAD-7;
Spitzer et al., 2006)
GAD-7 is based on the DSM-criteria for generalized anxiety
disorder (American Psychiatric Association, 2013). Each item is
reported on a four-point Likert scale (0, not at all; 3, almost
every day), and the answers refer to the past 2 weeks. GAD-7
has good psychometric properties and suggested cut-off scores
for identifying GAD range from 7 to 10 (Plummer et al., 2016;
Rutter and Brown, 2017).
The Work and Social Adjustment Scale (WSAS;
Mundt et al., 2002)
The WSAS is a short questionnaire measuring work and social
adjustment. The scale consists of five items rated from 0
(not at all) to 8 (very severe), and higher score indicates
higher impairment. The scale has good psychometric properties
(Cella et al., 2011).
Obsessive-Compulsive Inventory – Revised (OCI-R;
Foa et al., 2002)
The OCI-R is an 18-item self-rating scale, measuring six different
symptom dimensions of OCD. The OCI-R total score has high
test-retest reliability and high sensitivity to change (Foa et al.,
2002; Solem et al., 2010).
Dimensional Obsessive Compulsive Scale
Short-Form (DOCS-SF; Eilertsen et al., 2017)
The DOCS-SF is a self-report questionnaire adapted from the
28-item version of DOCS (Abramowitz et al., 2010). It consists
of a symptom checklist covering obsessive and compulsive
thoughts about “contamination,” “responsibility for harm, injury
or bad luck,” “unacceptable obsessional thoughts,” “symmetry
completeness and exactness.” For all dimensions, five items
are rated (0–8 scale) on (a) time occupied by obsessions and
compulsions, (b) avoidance behavior, (c) associated distress,
(d) interference with daily functioning, and (e) difficulty
disregarding obsessions and refraining from the compulsions.
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Items A and E are split into obsessions (0–4) and compulsions
(0–4). The total score ranges from 0 to 40.
The Client Socio-Demographic and Service Receipt
Inventory (CSSRI; Chisholm et al., 2000)
The CSSRI records socio-demographic data as well as previous
treatment history.
Client Satisfaction Questionnaire 8 (CSQ-8; Larsen
et al., 1979)
The CSQ-8 is an 8-item self-report scale on which patients report
their level of satisfaction with the treatment they have undergone.
The items are scored from 1 (very low satisfaction) to 4 (very high
satisfaction), which give a total score from 8 to 32. The CSQ-8 is
found to have good test-retest reliability and internal consistency
(Nguyen et al., 1983).
Treatment Completion, Response and
Remission
Treatment completion was defined as attending all 4 days.
Treatment response and remission were defined using a
modification of the international consensus criteria (Mataix-Cols
et al., 2016): Response is a ≥35% reduction of the individual
patient’s pre-treatment Y-BOCS score. A patient is remitted if
the response criterion is fulfilled and the post-treatment Y-BOCS
score is ≤12 points. In addition, we will use the categories
deterioration (≥35% increase of the individual patient’s pre-
treatment Y-BOCS score) and no change (neither a deterioration
nor a response).
Statistical Analyses
We used hierarchical linear modeling (HLM) with random
intercepts to compare the two exposure based interventions
(B4DT and SH) with the WL control condition. These
models estimate effects for change from pre-treatment to
post-treatment. In addition, interactions between time (pre-
treatment and post-treatment) and treatment condition can
be used to identify differences between conditions. Statistically
significant interactions were followed up by examination
of simple effects, with Bonferroni corrections for multiple
comparisons. This is recommended for the purpose of testing
pairwise combinations of levels of the within-subjects factor
(Maxwell and Delaney, 2014).
Similar HLM models were run for all primary and secondary
outcome measures. As there were significant differences between
conditions on PHQ-9, the pre-treatment score was included as
a covariate in the HLMs. A HLM was also used to examine
if the effect from the B4DT would be maintained at the 3-
month and 6-month follow-ups. This model therefore involved
the B4DT group only, and included four measurement points
(pre-treatment, post-treatment, 3- and 6-month follow-up).
The total non-response to the Y-BOCS interviews and self-
report measures used in this study was minimal. At pre-
treatment, all participants provided complete responses to all
measures. At post-treatment, 95.8% of the participants (n = 46)
provided complete responses, and the amount missing data
points totaled to 2.4%. Participants in the B4DT group also
received Y-BOCS-interviews at 3-month and 6-month follow-
up. At 3-month follow-up, 100% of the participants provided
complete data, whereas 87.5% provided complete data at 6-
month follow-up. Following the principle of intention to threat,
all participants were included in the analyses, irrespective of
missing data at any of the measurement points. Hierarchical
linear models do not assume balanced data and are able to
account for missing data on the response variable by using all
available data on each participant, and under the missing at
random (MAR) assumption, provide unbiased estimates (Schafer
and Graham, 2002; Molenberghs et al., 2004). HLM with
maximum likelihood estimation is often preferred over multiple
imputation because it involves fewer decisions to be made by the
researcher, is more efficient, and produces a deterministic result
(Allison, 2012). Unlike multiple imputation, which involves
introducing variability into the process, maximum likelihood is
deterministic and will always produce the same results when
applied to a given set of data.
Within group effect sizes were calculated using Cohen’s d,
defined as (Mpre − Mpost)/SDpre. Controlled between group
effect sizes were calculated post-treatment as: (Mean B4DT –
Mean SH or WL)/pooled standard deviation. Cut-offs for
interpreting effect sizes were: small (0.2), medium (0.5), and
large (0.8). Fisher’s exact probability test (2-tailed) was used
to compare differences between the treatment conditions on
dichotomous variables.
Ethical Approval
The study was reviewed and approved by the regional committee
of ethics for human research (REK Vest-2016/794). The trial
was pre-registered (ClinicalTrials.gov Identifier: NCT02886780)
as a RCT comparing the Bergen 4-day concentrated exposure




Results for the primary and secondary outcome measures are
presented in Table 2.
Change in OCD Symptoms
There was a statistically significant difference in the average
change from pre-treatment to post-treatment in favor of the two
intervention groups, χ2(2) = 138.17, p < 0.001. Compared to
the WL group, both the B4DT group (−16.48, 95% CI [−19.79,
−13.17], p < 0.001) and the SH group (−3.62, 95% CI [−6.89,
−0.35], p = 0.026) had a greater decrease in their Y-BOCS scores
from pre- to post-treatment. Simple effects at post-treatment
showed that the mean Y-BOCS score was significantly lower for
the B4DT group compared with the WL group (−16.24, 95% CI
[−20.10, −12.37], p < 0.001) and the SH group (−13.05, 95% CI
[−17.23, −8.87], p < 0.001). There was no statistically significant
difference between the means of the SH and the WL groups
at post-treatment (−3.19, 95% CI [−7.10, 0.72], p = 0.153).
Effect sizes (ES) are presented in Table 2. The B4DT had large


















TABLE 2 | Means (SDs) for Y-BOCS, GAD-7, PHQ-9, DOCS-SF, OCI-R, and WSAS.
Measure Treatment Pre Post 3-m FU 6-m FU Effect size (d) within group Effect size (d) between groups
post-treatment
M (SD) M (SD) M (SD) M (SD) pre–post pre-3-m FU pre-6-m FU B4DT vs. SH B4DT vs. WL SH vs. WL
Y-BOCS B4DT 26.75 (4.23) 10.90 (4.35) 8.56 (5.75) 9.17 (6.89) 3.75 4.30 4.16 2.57 3.86 0.51
SH 27.88 (4.22) 24.63 (6.18) 0.77
WL 26.88 (3.93) 27.32 (4.14) −0.11
DOCS-SF B4DT 26.56 (3.81) 13.44 (7.08) 10.69 (8.18) 12.00 (8.16) 3.44 4.17 3.82 1.65 1.87 0.10
SH 28.69 (3.61) 24.63 (6.47) 0.57
WL 28.56 (6.29) 25.24 (5.43) 0.53
OCI-R B4DT 22.69 (12.42) 7.94 (5.94) 6.13 (5.48) 8.06 (8.16) 1.19 1.33 1.18 1.38 1.67 0.24
SH 29.25 (15.29) 22.00 (13.14) 0.47
WL 27.69 (14.42) 25.19 (13.38) 0.17
PHQ-9 B4DT 10.06 (4.60) 5.81 (4.37) 4.81 (3.97) 5.44 (3.77) 0.92 1.14 1.00 1.44 1.74 0.04
SH 16.31 (5.69) 12.63 (5.06) 0.65
WL 12.50 (3.65) 12.48 (3.21) 0.01
GAD-7 B4DT 10.69 (4.21) 6.81 (3.89) 5.00 (3.71) 6.68 (4.69) 0.92 1.35 0.95 1.24 1.24 0.04
SH 13.81 (3.97) 12.44 (5.10) 0.35
WL 13.60 (4.85) 12.24 (4.81) 0.28
WSAS B4DT 15.13 (8.31) − 6.19 (7.48) 6.38 (6.04) − 1.08 1.05 – – –
SH 19.38 (7.20) 18.19 (6.93) 0.17
WL 21.81 (7.16) 20.27 (6.51) 0.22
Y-BOCS, Yale-Brown Obsessive Compulsive Scale; GAD-7, generalized anxiety disorder-7; PHQ-9, patient health questionnaire-9; DOCS-SF, dimensional obsessive compulsive scale – short form; OCI-R, obsessive
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within-group as well as between-group ESs compared to both
the SH- and the WL-condition. The SH-condition had a large
within-group ES and a medium between-group ES compared to
the WL-condition.
A separate HLM involving the B4DT group only was
conducted to examine if the effects gained from the treatment
would remain over the two follow-ups. Two planned
comparisons (3-month follow-up vs. post-treatment; 6-month
follow-up vs. post-treatment) showed that mean Y-BOCS scores
did not significantly change from post-treatment to 3-month
follow-up (−2.20, 95 CI [−5.31, 0.90], p = 0.22) or from
post-treatment to 6-month follow-up (−1.39, 95 CI [−4.62,
1.85], p = 0.67).
The B4DT was highly accepted by the patients, as indicated by
the proportion of patients that accepted to participate in the RCT
(98%), and the fact that all patients completed the treatment.
Response and Remission
At post-treatment the response rate was 93.8% in B4DT
compared to 12.5% in SH, and 0% in WL. The rates of remission
were 62.5%, 6.3%, and 0%, respectively. A chi-square test yielded
a significant χ2 (4) = 36.4, p < 0.0001, showing that the B4DT
had significantly better clinical response than SH and WL, which
did not differ from each other.
Table 3 displays the clinical improvement for the B4DT
comparing post-treatment and 6-month follow-up. Nine of the
10 patients who were in remission post-treatment remained in
that category at follow-up, whereas one had a small worsening
to the response category. Even more interesting is that four
of the five (80%) responders post-treatment had advanced to
the remission category at follow-up, whereas one backed down
to the no change category. These changes yielded a follow-up
remission rate of 81.3% compared to 62.5% at post-treatment, a
non-significant difference (McNemar’s test 2-tailed, p = 0.37).
All patients in the WL and 14 of the patients (87.5%) in
the SH condition still fulfilled criteria for an OCD-diagnosis
according to the SCID-I interview at post-treatment assessment.
In comparison, 13 (81.3%) of the patients in the B4DT condition
no longer met criteria for an OCD-diagnosis. This was a
significant difference between the B4DT and the WL condition
(Fisher’s exact test, p < 0.001) and the SH condition (Fisher’s
exact test, p < 0.001).
Secondary Outcome Measures
Self-Reported OCD-Symptoms
HLMs were conducted to compare the treatment effect on
self-reported OCD-symptoms, as measured by DOCS-SF and
OCI-R. There was a statistically significant difference in the
average change from pre-treatment to post-treatment in favor
of the B4DT group for DOCS-SF, χ2(2) = 30.25, p < 0.001.
The decrease for the B4DT group was significantly larger than
for the WL group (−9.65, 95% CI [−14.10, −5.21], p < 0.001).
The change from pre- to post-treatment for the SH group was
not significantly different from the WL group (−0.59, 95% CI
[−5.04, 3.85], p = 1.00). Simple effects at post-treatment showed
that the mean DOCS-SF score was significantly lower for the
B4DT group compared with the WL group (−11.30, 95% CI
[−16.00, −6.60], p < 0.001) and the SH group (−10.27, 95% CI
[−15.33, −5.22], p < 0.001). There was no statistically significant
difference between the means of the SH and the WL groups at
post-treatment (−1.02, 95% CI [−5.83, 3.78], p = 1.00).
Likewise, there was a statistically significant difference in the
average change from pre-treatment to post-treatment in favor
of the B4DT group for OCI-R, χ2(2) = 14.05, p < 0.001. The
B4DT group reported a significantly larger decrease in mean
OCI-R score from pre- to post-treatment than the WL group
(−12.24, 95% CI [−19.64, −4.84], p < 0.001). The change from
pre- to post-treatment for the SH group was not significant
(−4.74, 95% CI [−12.14, 2.66], p = 0.30). Multiple between-
group comparisons revealed that the mean for the B4DT group
was significantly different from the WL group (−16.02, 95%
CI [−26.65, −5.39], p < 0.01) but not from the mean of the
SH group at post-treatment (−10.92, 95% CI [−22.56, 0.71],
p= 0.07). The difference in means between the WL and SH groups
at post-treatment was not statistically significant (−5.09, 95% CI
[−16.01, 5.81], p = 0.79).
Self-Reported Depressive Symptoms and
Generalized Anxiety
There was a statistically significant interaction between time
and condition for PHQ-9, χ2(2) = 11.24, p < 0.001. Both the
B4DT group (−4.22, 95% CI [−7.27, −1.17], p < 0.001) and
the SH group (−3.66, 95% CI [−6.71, −0.61], p = 0.014) had
greater decreases in PHQ-9 scores from pre- to post-treatment
than the WL group. Simple effects at post-treatment showed
TABLE 3 | Clinical improvement for the B4DT post-treatment and at 6-month follow-up.
Status at 6-month follow-up
Status at post-treatment Remission Response No change Deterioration Total
Remission 9 1 0 0 10 (62.5%)
Response 4 0 1 0 5 (31.3%)
No change 0 0 1 0 1 (6.3%)
Deterioration 0 0 0 0 0
Total 13 (81.3%) 1 (6.3%) 2 (12.5%) 0 16
Treatment response was calculated based on the international consensus criteria (Mataix-Cols et al., 2016) which require a ≥35% reduction of the individual patient’s
pre-treatment Y-BOCS score in order to be classified as a clinically relevant response. A patient is classified as remitted if, in addition to response, the post-treatment
Y-BOCS score is ≤12 points.
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that the mean PHQ-9 score was significantly lower for the
B4DT group compared with both the WL group (−6.66, 95% CI
[−10.40, −2.92], p < 0.001) and the SH group (−6.81, 95% CI
[−10.52, −3.11], p < 0.001). There was no statistically significant
difference between the means of the SH and the WL groups at
post-treatment (0.15, 95% CI [−3.59, 3.90], p = 1.00). There was
no statistically significant interaction between time and condition
for GAD-7, χ2(2) = 3.47, p = 0.18. There was, however, a main
effect of time, indicating a general decrease in GAD-7 scores
for all groups (−2.38, 95% CI [−3.52, −1.24], χ2(1) = 16.74,
p < 0.001).
Self-Reported Work and Social Adjustment
There was a statistically significant difference in favor of the
B4DT group for WSAS (B4DT follow-up vs. SH and WL post-
treatment), χ2(2) = 13.22, p < 0.001. The change for the B4DT
group was significantly larger than the change for the WL group
(−7.52, 95% CI [−13.00, −2.03], p < 0.001). There was no
statistically significant difference between the SH and WL groups
(0.23, 95% CI [−5.25, 5.71], p = 1.00). Multiple between-group
comparisons showed that the mean WSAS score was significantly
lower for the B4DT group compared with both the WL group
(−13.42, 95% CI [−19.43, −7.41], p < 0.001) and the SH group
(−9.98, 95% CI [−16.47, −3.50], p < 0.001). There was no
statistically significant difference between the means of the SH
and the WL groups at post-treatment (−3.43, 95% CI [−9.58,
2.71], p = 0.54).
Patient Satisfaction With Health Services
The patients in the B4DT-condition reported very high
satisfaction, measured with CSQ-8 (possible range 8–32) post-
treatment, M = 29.69, SD = 2.62, range 24–32). See Table 4 for
further details.
DISCUSSION
The aim of this study was to compare the clinical effects
of the Bergen 4-day treatment for patients with OCD, to
a SH intervention based on the Foa and Kozak (1997)
treatment approach in an RCT with WL as the control
TABLE 4 | Post-treatment scores on Client Satisfaction Questionnaire 8 for
patients treated with B4DT.
Satisfaction rating
Item 1 2 3 4
Quality of service 0 0 5 11
Kind of service 0 0 5 11
Met needs 0 0 7 9
Recommend to friend 0 0 2 14
Amount of help 0 0 5 11
Dealt with problems 0 0 5 11
Overall satisfaction 0 0 3 13
Come back 0 0 5 11
N = 16. Items are scored on a Likert scale from 1 (low satisfaction) to 4 (high
satisfaction).
condition. As expected, the clinical changes observed
following the B4DT were superior to the SH-condition
and the WL-control. More than 93% of the patients in the
B4DT responded post treatment, and the remission rate
was nearly 63%, which was increased to 81% at 6-month
follow-up. Two of the patients who received SH, both with
moderate OCD-symptoms initially, achieved remission
after the intervention, whereas none of the patients in the
WL-condition did so.
The B4DT was highly accepted by the patients, as measured by
the proportion of patients that accepted to participate in the RCT
(98%). Also, there was no attrition since all patients completed
the treatment. The patients reported high satisfaction with the
treatment as indicated by a mean score of 29.69 on a scale with a
maximum of 32. It is also noteworthy that this scale specifically
asks if this was the kind of treatment they wanted, and whether
they considered the amount of treatment to be satisfactory. The
B4DT also improved depressive symptoms, generalized anxiety
symptoms, and work and social adjustment.
The results for the patients treated with the B4DT are basically
the same as have been found in a number of uncontrolled
effectiveness studies (Havnen et al., 2014, 2017; Hansen et al.,
2018) conducted by the originators of the B4DT, and replicated at
new sites (Kvale et al., 2018; Launes et al., 2019), as well as in a new
country (Davíðsdóttir et al., 2019). The Norwegian uncontrolled
studies yielded post-treatment Y-BOCS means between 9.0 and
10.9, and the present study had a mean of 10.9; the follow-up
means ranged between 10.0 and 10.8, whereas the present study
had 9.2. Regarding remission rate the uncontrolled studies varied
between 72% and 77%, but the present study was somewhat
lower at 63%. However, at follow-up the present RCT had a
somewhat higher rate at 81%, compared to the uncontrolled
studies’ range of 60–77%.
A comparison of the effects of B4DT with those in RCTs
of standard (not concentrated) ERP in our meta-analysis (Öst
et al., 2015) is of interest. In the meta-analysis, non-concentrated
ERP yielded a remission rate of 48% both post-treatment and
at follow-up 3–12 months later. Thus, the 63% post and 81% at
follow-up (after 6 months) for B4DT in the present study are
promising, but it would take an RCT directly comparing these
formats to ascertain if the concentrated treatment is superior to
treatment with weekly sessions.
There were no significant OCD-related pre-treatment
differences between the patients randomized to the different
conditions. However, depressive symptoms, including both
major depression and dysthymia, were significantly higher in
the SH- compared to the B4DT-condition, as indicated both by
structured clinical interview and self-report.
The results indicated that the SH intervention was not
superior to the wait-list condition, even though two patients
remitted following SH. This finding is in line with previous
findings by, e.g., Moritz et al. (2011) and Schneider et al.
(2015) who also employed a SH intervention without any
therapist assistance.
We believe that the patients in the current study are
representative of the patients seeking treatment for OCD in
specialist health care settings. The trial was conducted at an
outpatient clinic were B4DT is given as standard treatment for
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OCD. Only two patients declined to participate in the study. Both
patient characteristics and results are very similar to previous
studies of B4DT conducted in the specialized health care setting
(Havnen et al., 2014, 2017; Hansen et al., 2018, 2019). Nearly
ninety percent were suffering from severe OCD and 87% of the
patients had at least one co-morbid disorder.
A potential challenge and limitation of the present trial,
is that we did not systematically record whether the patients
actually read and used the SH manual. This is in line
with previous trials (e.g., Vogel et al., 2014), and this
decision was made in order to ensure that the patients
randomized to SH did not have any therapist contact during
the intervention. It should, however, be noted that two
of the patients in the SH condition remitted, which is
an indication that the SH book was adequate for these
patients. The controlled effect size of SH vs. WL was
d = 0.51. Unfortunately, there is no RCT of self-administered
bibliotherapy of ERP in the literature, but two RCTs of
predominantly SH with this content. (Tolin et al., 2007) found
a d = 0.65 and Vogel et al. (2014) reported a d = 0.13.
Thus, SH in the present study was at least as good as the
mean ES in these two studies. As B4DT were found to
be more effective than SH and waiting-list, further studies
should compare the treatment to more effective treatments
such as therapist assisted SH, face-to-face CBT, internet
delivered CBT, or SSRI.
Another potential challenge is the fact that all patients
ahead of randomization, were granted the B4DT post
SH/WL if they experienced a need for it, which might
have affected their motivation to actually use the SH
program. This is a common ethical challenge in this
kind of clinical studies, and in Norway, where all OCD-
patients are offered evidence-based treatment; it would not
have been ethically approved to not offer ERP to patients
randomized to SH or WL.
Even though patients with a previous full course of ERP-
treatment were not part of this study, the patients in the
current trial did not differ in OCD severity; duration of
the disorder; number of comorbid disorders, or amount of
previous contact with the specialist health care as compared
to the patients in the previous open trials. Although the
study was sufficiently powered to detect significant differences
between conditions, the relatively small sample size is a
limitation when comparing results for the current study to
related treatments.
With respect to dissemination and allegiance aspects of the
treatment, issues such as an international manual, therapist
training, and certification of teams need to be addressed in
future studies. The current study did not include qualitative
research on patient- and therapist perspectives on the treatments
included. Future studies could also systematically investigate
these experiences.
In conclusion, results add to the literature supporting the
effectiveness of B4DT.
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